What does CND Life Sciences do?
CND Life Sciences is a neurodiagnostics startup based in Scottsdale, AZ, that operates a CLIA-certified and CAP-accredited laboratory. The company has developed the Syn-One Test, a cutting-edge assay that uses proprietary immunofluorescence techniques to diagnose synucleinopathies such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, and REM sleep behavior disorder.
How much did they raise?
The company raised $13.5M in its Series A funding round, which included an $8.6M Series A3 offering. The round saw participation from investors such as Cambrian Capital Partners, Tanis Ventures, Lupo Labs, Top Corner Capital, HonorHealth, Triana, Gold Bench Capital, BlueStone Ventures, Labcorp, MBX Capital, and Vilas Ventures, with the effort led by CEO Rick Morello and Chief Scientific Officer Christopher Gibbons.
What are their plans for the money?
With the new capital, CND Life Sciences plans to enhance its diagnostic offerings and expand clinical collaborations. The funding will help improve early detection capabilities and support ongoing studies and clinical trials for investigational therapies, potentially transforming patient care for neurodegenerative diseases.
What have they achieved so far?
The Syn-One Test is already making an impact, having been used by nearly 3,000 neurologists and clinicians across all 50 states. Its adoption in clinical settings and involvement in biopharmaceutical trials underscore its efficacy and the company’s progress in the neurodiagnostics field.
